Autier Philippe, Boniol Mathieu, Smans Michel, Sullivan Richard, Boyle Peter
Institute of Global Public Health at iPRI, International Prevention Research Institute, University of Strathclyde, Ecully Lyon 69130, France International Prevention Research Institute (iPRI), Lyon 69006, France
Institute of Global Public Health at iPRI, International Prevention Research Institute, University of Strathclyde, Ecully Lyon 69130, France International Prevention Research Institute (iPRI), Lyon 69006, France.
J R Soc Med. 2015 Nov;108(11):440-50. doi: 10.1177/0141076815593403. Epub 2015 Jul 7.
We compared calculations of relative risks of cancer death in Swedish mammography trials and in other cancer screening trials.
Men and women from 30 to 74 years of age.
Randomised trials on cancer screening.
For each trial, we identified the intervention period, when screening was offered to screening groups and not to control groups, and the post-intervention period, when screening (or absence of screening) was the same in screening and control groups. We then examined which cancer deaths had been used for the computation of relative risk of cancer death.
Relative risk of cancer death.
In 17 non-breast screening trials, deaths due to cancers diagnosed during the intervention and post-intervention periods were used for relative risk calculations. In the five Swedish trials, relative risk calculations used deaths due to breast cancers found during intervention periods, but deaths due to breast cancer found at first screening of control groups were added to these groups. After reallocation of the added breast cancer deaths to post-intervention periods of control groups, relative risks of 0.86 (0.76; 0.97) were obtained for cancers found during intervention periods and 0.83 (0.71; 0.97) for cancers found during post-intervention periods, indicating constant reduction in the risk of breast cancer death during follow-up, irrespective of screening.
The use of unconventional statistical methods in Swedish trials has led to overestimation of risk reduction in breast cancer death attributable to mammography screening. The constant risk reduction observed in screening groups was probably due to the trial design that optimised awareness and medical management of women allocated to screening groups.
我们比较了瑞典乳房X线摄影试验及其他癌症筛查试验中癌症死亡相对风险的计算结果。
年龄在30至74岁之间的男性和女性。
癌症筛查的随机试验。
对于每项试验,我们确定了干预期(即向筛查组提供筛查而对照组不提供筛查的时期)和干预期后时期(即筛查组和对照组的筛查情况相同的时期)。然后,我们检查了哪些癌症死亡病例被用于计算癌症死亡的相对风险。
癌症死亡的相对风险。
在17项非乳腺筛查试验中,干预期和干预期后时期诊断出的癌症导致的死亡被用于相对风险计算。在瑞典的5项试验中,相对风险计算使用了干预期发现的乳腺癌导致的死亡病例,但对照组首次筛查时发现的乳腺癌导致的死亡病例被加入到这些组中。将这些额外增加的乳腺癌死亡病例重新分配到对照组的干预期后时期后,干预期发现的癌症的相对风险为0.86(0.76;0.97),干预期后时期发现的癌症的相对风险为0.83(0.71;0.97),这表明在随访期间乳腺癌死亡风险持续降低,与筛查无关。
瑞典试验中使用的非常规统计方法导致了对乳房X线摄影筛查所致乳腺癌死亡风险降低的高估。筛查组中观察到的持续风险降低可能归因于优化了分配到筛查组的女性的认知度和医疗管理的试验设计。